X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Cadila Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs CADILA HEALTHCARE - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA CADILA HEALTHCARE SUN PHARMA/
CADILA HEALTHCARE
 
P/E (TTM) x 25.7 32.8 78.5% View Chart
P/BV x 3.8 6.5 57.9% View Chart
Dividend Yield % 0.6 0.7 84.4%  

Financials

 SUN PHARMA   CADILA HEALTHCARE
EQUITY SHARE DATA
    SUN PHARMA
Mar-17
CADILA HEALTHCARE
Mar-17
SUN PHARMA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs842460 183.1%   
Low Rs572305 187.7%   
Sales per share (Unadj.) Rs131.692.1 142.9%  
Earnings per share (Unadj.) Rs32.714.8 220.7%  
Cash flow per share (Unadj.) Rs38.018.5 205.5%  
Dividends per share (Unadj.) Rs3.503.20 109.4%  
Dividend yield (eoy) %0.50.8 59.2%  
Book value per share (Unadj.) Rs152.768.0 224.6%  
Shares outstanding (eoy) m2,399.261,023.74 234.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.44.2 129.4%   
Avg P/E ratio x21.625.8 83.8%  
P/CF ratio (eoy) x18.620.7 90.0%  
Price / Book Value ratio x4.65.6 82.3%  
Dividend payout %10.721.6 49.6%   
Avg Mkt Cap Rs m1,696,877391,581 433.3%   
No. of employees `00017.516.9 103.9%   
Total wages/salary Rs m49,02315,002 326.8%   
Avg. sales/employee Rs Th18,028.35,594.5 322.3%   
Avg. wages/employee Rs Th2,798.8890.1 314.4%   
Avg. net profit/employee Rs Th4,479.5899.9 497.8%   
INCOME DATA
Net Sales Rs m315,78494,295 334.9%  
Other income Rs m6,2321,286 484.6%   
Total revenues Rs m322,01695,581 336.9%   
Gross profit Rs m100,89319,036 530.0%  
Depreciation Rs m12,6483,750 337.3%   
Interest Rs m3,998450 888.4%   
Profit before tax Rs m90,47916,122 561.2%   
Minority Interest Rs m0338 0.0%   
Prior Period Items Rs m990-   
Extraordinary Inc (Exp) Rs m0-3 0.0%   
Tax Rs m12,1161,289 939.9%   
Profit after tax Rs m78,46215,168 517.3%  
Gross profit margin %31.920.2 158.3%  
Effective tax rate %13.48.0 167.5%   
Net profit margin %24.816.1 154.5%  
BALANCE SHEET DATA
Current assets Rs m329,53760,223 547.2%   
Current liabilities Rs m178,87053,058 337.1%   
Net working cap to sales %47.77.6 627.9%  
Current ratio x1.81.1 162.3%  
Inventory Days Days7970 113.1%  
Debtors Days Days8388 94.4%  
Net fixed assets Rs m204,76672,984 280.6%   
Share capital Rs m2,3991,024 234.3%   
"Free" reserves Rs m363,99768,576 530.8%   
Net worth Rs m366,39769,600 526.4%   
Long term debt Rs m14,36124,684 58.2%   
Total assets Rs m614,102152,207 403.5%  
Interest coverage x23.636.8 64.2%   
Debt to equity ratio x00.4 11.1%  
Sales to assets ratio x0.50.6 83.0%   
Return on assets %13.410.3 130.9%  
Return on equity %21.421.8 98.3%  
Return on capital %24.817.9 138.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m44,11821,280 207.3%   
Fx outflow Rs m24,48410,874 225.2%   
Net fx Rs m19,63410,406 188.7%   
CASH FLOW
From Operations Rs m70,82213,495 524.8%  
From Investments Rs m-42,216-29,103 145.1%  
From Financial Activity Rs m-22,85423,158 -98.7%  
Net Cashflow Rs m6,1077,556 80.8%  

Share Holding

Indian Promoters % 63.7 74.8 85.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 8.3 61.8%  
FIIs % 23.0 5.9 389.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 11.0 75.5%  
Shareholders   133,026 44,069 301.9%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   TTK HEALTHCARE  ALEMBIC LTD  CIPLA  ELDER PHARMA  SUVEN LIFE  

Compare SUN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Of Global Markets Hitting Record Highs and Top Stocks in Action During the Week(RoundUp)

Global stock markets ended the week on a positive note. Benchmark indices in US grew by 1% during the week. The Down Jones Industrial Average topped the 26,000.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Jan 19, 2018 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE SUN PHARMA WITH

MARKET STATS